Am J Physiol Cell Physiol Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Cell Physiol 290: C719-C727, 2006. First published October 26, 2005; doi:10.1152/ajpcell.00419.2005
0363-6143/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/3/C719    most recent
00419.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, F. C.
Right arrow Articles by Ogut, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, F. C.
Right arrow Articles by Ogut, O.

MUSCLE CELL BIOLOGY AND CELL MOTILITY

Decline of contractility during ischemia-reperfusion injury: actin glutathionylation and its effect on allosteric interaction with tropomyosin

Frank C. Chen and Ozgur Ogut

Cardiovascular Contractility and Signaling Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota

Submitted 18 August 2005 ; accepted in final form 19 October 2005


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The severity and duration of ischemia-reperfusion injury is hypothesized to play an important role in the ability of the heart subsequently to recover contractility. Permeabilized trabeculae were prepared from a rat model of ischemia-reperfusion injury to examine the impact on force generation. Compared with the control perfused condition, the maximum force (Fmax) per cross-sectional area and the rate of tension redevelopment of Ca2+-activated trabeculae fell by 71% and 44%, respectively, during ischemia despite the availability of a high concentration of ATP. The reduction in Fmax with ischemia was accompanied by a decline in fiber stiffness, implying a drop in the absolute number of attached cross bridges. However, the declines during ischemia were largely recovered after reperfusion, leading to the hypothesis that intrinsic, reversible posttranslational modifications to proteins of the contractile filaments occur during ischemia-reperfusion injury. Examination of thin-filament proteins from ischemic or ischemia-reperfused hearts did not reveal proteolysis of troponin I or T. However, actin was found to be glutathionylated with ischemia. Light-scattering experiments demonstrated that glutathionylated G-actin did not polymerize as efficiently as native G-actin. Although tropomyosin accelerated the time course of native and glutathionylated G-actin polymerization, the polymerization of glutathionylated G-actin still lagged native G-actin at all concentrations of tropomyosin tested. Furthermore, cosedimentation experiments demonstrated that tropomyosin bound glutathionylated F-actin with significantly reduced cooperativity. Therefore, glutathionylated actin may be a novel contributor to the diverse set of posttranslational modifications that define the function of the contractile filaments during ischemia-reperfusion injury.

force; troponin; cooperativity

THE OCCLUSION OF AN ARTERY is a primary cause of myocardial ischemia, the physiological condition of low or no blood flow that results in O2 deprivation in the myocardium. This condition may occur in an acute setting as a result of rupture of an atherosclerotic lesion and consequent occlusion due to atherothrombosis (15). The duration and extent of the ischemic period is thought to be a primary determinant of the chance of consequent infarction, with as little as 15 min of proximal coronary occlusion resulting in some degree of irreversible cell injury (28, 33). The interruption of blood flow with coronary occlusion causes rapid consumption of available O2 in affected areas of the myocardium, shifting the cell from aerobic to anaerobic metabolism (28). This condition results in a rapid and large (>40%) decline in ATP and creatine phosphate (CP) content in cardiomyocytes (5, 6, 9, 24, 42, 43, 62) that is readily apparent within 10 min of the onset of ischemia. Because ATP is the substrate for the actomyosin ATPase, its large decline during ischemia suggests that this is a causative event for the decrease in force produced by ischemic myocardium. However, concentrations of ATP during ischemia remain well above the Km of myosin (9, 14, 43, 62), suggesting that reductions in ATP cannot solely explain the observed decline in the contractility of the heart. Therefore, additional mechanisms are hypothesized to impair force production during ischemia-reperfusion injury.

Studies of the molecular consequences of ischemia-reperfusion injury suggest that specific proteolysis of sarcomeric proteins may play a prominent role (13, 22, 54, 58). Specifically, cleavage of troponin I (TnI), the inhibitory subunit of the troponin complex, was shown to occur at the COOH terminus of the protein. Van Eyk et al. (54) suggested that the observed cleavage of sarcomeric proteins during ischemia-reperfusion injury correlated with a decline in force production along with a change in the Ca2+ sensitivity of the muscle fibers. The functional consequences of this protein cleavage have been studied in a transgenic mouse line expressing the truncated TnI protein TnI1–193 (34, 41). In addition, specific cleavage of troponin T (TnT), the tropomyosin (Tm)-binding subunit of the troponin complex, may also occur (12), possibly through a caspase-mediated pathway (13). In addition to proteolysis, posttranslational modification of proteins resulting from changes in the cell redox state have been observed during ischemia-reperfusion or other inflammatory injury (19, 20). The formation of reactive oxygen species is postulated as an additional cause of protein damage during ischemia-reperfusion injury, resulting in the oxidation of proteins at susceptible amino acids (1, 2). The impact of proteins modified by reactive oxygen species may be regulated by reversal of the modification (35, 39, 60, 61) or by the protein's subsequent proteolysis by the proteasome (21, 49). However, it has been established that such modifications are not summarily negative but may play a role in modulating protein activity (31, 32, 56, 63). It is therefore hypothesized that changes in the cell redox state in ischemia-reperfusion injury may target proteins of the actomyosin filaments to regulate contractility during, and recovery from, the ischemic state (19). Such protein targets would be of particular interest, as they might contribute directly to acute changes in myocardial contractility.

To examine contractile function during ischemia-reperfusion injury, permeabilized trabeculae from a rat model were used to measure force generation in the presence and absence of external load. The results demonstrated a reduction in the maximum force (Fmax) per cross-sectional area, the rate of tension redevelopment (Ktr), and fiber stiffness with ischemia that was not rescued by ATP, suggesting that posttranslational modification of contractile filament proteins may be involved. These changes in contractile function during ischemia were accompanied by the appearance of a glutathionylated form of sarcomeric actin (19, 57). Additional data are provided to suggest that glutathionylation of actin may alter its allosteric interaction with Tm, providing a novel point for further study of the effect of ischemia-reperfusion injury on cardiac muscle thin-filament function.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Ischemia-reperfusion injury model. This model was described in detail previously (7). Male Sprague-Dawley rats were anesthetized using intramuscular xylazine, ketamine HCl, and acepromazine (3:3:2; 0.5–0.75 ml/kg) in accordance with protocols approved by the Institutional Animal Care and Use Committee. An endotracheal tube was inserted for ventilation with O2-supplemented room air with the use of a positive pressure respirator (5–15 mmHg). Body temperature was maintained at 37°C during the procedure. The heart was exposed by performing a midline thoracotomy, and a ligature was placed around the left anterior descending coronary artery close to its origin from the aorta. The ends were exteriorized and passed through polyethylene tubing. Coronary occlusion was achieved by pressing the tube against the heart muscle while pulling the ligature, followed by clamping the tube with a hemostat. Reflow was initiated by releasing the ligature. Experimental conditions tested included 90-min control perfusion and up to 30 min of left anterior descending coronary occlusion (ischemia), followed by 0 or 60 min of reperfusion. Trabeculae were prepared from the ischemic zone of the left ventricle.

Contractility measurements. The procedures and solutions used in the muscle preparations were described previously (45). Trabeculae from the left ventricle were excised, and their ends were fixed using 1% glutaraldehyde in 50% glycerol (10), followed by attachment of aluminum T-clips. Trabeculae were skinned for 60 min at 4°C in pCa9 (1 x 10–9 M free Ca2+) solution with 1% Triton X-100 and then transferred to a workstation (45). The trabeculae were stretched to an average sarcomere length of ~2.2 µm (45), and the length of the fiber was recorded as original length. Trabeculae were activated with solutions containing various free Ca2+ concentrations ([Ca2+]). Force generated was normalized to Fmax by calculating the elliptical cross-sectional area of the fiber. Experiments were temperature controlled to 15 ± 0.1°C. Measurements predicated on controlling the length or force of the fiber were programmed using the 600A Controller device (Aurora Scientific, Aurora, ON, Canada). Ktr experiments were performed as described previously (45). At least six measurements of Ktr were taken from each fiber. Data regarding force as a function of free Ca2+ were fit using the Hill equation to determine the concentration of free Ca2+ required to reach half-maximal force (Ca502+) as well as to determine the cooperativity of force activation, or Hill coefficient (nH). The maximum velocity (Vmax) of shortening was determined by isotonic contractions at various percentages of Fmax (3–100%). Each isotonic contraction was performed in triplicate. Velocities were normalized to muscle lengths (ML) per second, plotted as a function of force, and fit by the Hill equation (14, 27) to determine the extrapolated velocity at zero force. Fiber stiffness was measured as described previously (46). Data are presented as averages ± SE. Statistical comparisons between groups were performed using Student's t-test.

One- and two-dimensional SDS-PAGE. For resolution of thin-filament proteins according to Mr, a 29:1 SDS-PAGE ratio of various acrylamide concentrations was used (46, 47). For two-dimensional PAGE, the muscle was extracted with 7 M urea, 2 M thiourea, 4% 3-([3-cholamidopropyl]dimethylammonio)-2-hydroxy-1-propanesulfonate (CHAPS), 0.5% pH 3–10 immobilized pH gradient (IPG) buffer, 1 mM EDTA, and 1 mM PMSF. Proteins were extracted from Triton X-100-permeabilized muscle strips to ensure that the fiber contraction and resulting protein expression pattern could be correlated reliably. For resolution of actin isoelectric variants, appropriate protein amounts from the extracts were added to a solution containing 7 M urea, 2 M thiourea, 2% CHAPS, 0.5% IPG buffer, and 0.002% bromophenol blue and were allowed to rehydrate pH 4–7 IPG gel strips overnight. After rehydration, proteins were focused in "face-up" mode on an Ettan IPGphor II system (Amersham Biosciences, Piscataway, NJ). After isoelectric point separation, the gel strips were equilibrated in 6 M urea, 50 mM Tris·HCl, pH 8.8, 30% glycerol, 2% SDS, and 0.002% bromophenol blue with DTT and iodoacetamide before resolution using Mr in the second dimension. After SDS-PAGE was completed, gels were used for Western blotting or were silver stained as described previously (47). To test the reversibility of observed modifications, duplicate isoelectric point-focusing experiments were conducted in the presence of DTT, a sulfhydryl-reducing agent.

Western blot analysis. PAb antisera against TnT and TnI (10-T85 and TnI 88-106, respectively; Fitzgerald Industries International, Concord, MA) or MAb against sarcomeric actin (Sigma, St. Louis, MO) were used for Western blot analysis (47). To test for TnI and TnT proteolysis, three sets of perfused, ischemic, and ischemia-reperfusion homogenates were used. To ensure that proteins cleaved at either the NH2- or COOH-terminal end would be detected reliably, antisera directed against epitopes of the central region of the proteins were used. To detect protein glutathionylation, an anti-glutathione antibody (ViroGen, Watertown, MA) was used. Signals were visualized using alkaline phosphatase substrate development or ECL detection.

Immunoprecipitation. Immunoprecipitation of actin was performed with the specific actin antibody and anti-mouse IgM agarose beads (Sigma). An aliquot of homogenate from a permeabilized fiber was dissolved in 1 ml of actin depolymerization buffer (in mM: 2 Tris·HCl, pH 8, 0.2 CaCl2, and 0.2 ATP) and incubated for 30 min at 4°C. The lysate was centrifuged to remove insoluble proteins. Subsequently, 1 µg of actin antibody was added and mixed at 4°C for 2 h, followed by addition of anti-mouse IgM agarose beads and further incubation for 30 min at 4°C. The bead-antibody-antigen complexes were recovered by performing brief centrifugation, washed twice with 10 bead volumes of actin depolymerization buffer, and incubated for 5 min at 60°C in SDS-PAGE sample buffer. The recovered sample was used for Western blot analysis.

Protein purification. Actin was purified from rabbit skeletal muscle acetone powder (48). Polymerization and depolymerization of actin was achieved as described previously (48). Cardiac muscle Tm, predominantly the {alpha}-isoform, was purified from chicken heart (Pel-Freez Biologicals, Rogers, AR) according to a previously published protocol (50). Proteins were quantitated using the Nanoorange protein assay (Molecular Probes, Eugene, OR), as well as absorbance for globular actin (G-actin) with a molar extinction coefficient of 26,460 cm–1·M–1 (16).

Actin glutathionylation. Purified G-actin was glutathionylated using a previously described method (16, 18). A solution of 30 µM G-actin was reacted with a 20-fold excess of 20 mM DTNB in 1% NaHCO3 until an equivalent molar amount of DTNB– was released as followed using A412 nm. This mixture was gel filtered through Sephadex G25 (Sigma), mixed with a 50-fold molar excess of glutathione, and allowed to react for 20 min at room temperature. The final product was gel filtered and then dialyzed against actin depolymerization buffer, followed by a polymerization-depolymerization cycle (48). Glutathionylation was verified using Western blot analysis, and the ratio of glutathionylated to native G-actin was determined by resolution of the two forms using isoelectric focusing, followed by silver staining and quantitation using a Personal Densitometer SI and ImageQuant software (Amersham Biosciences). The fraction of glutathionylated G-actin was calculated by dividing the value of the glutathionylated G-actin spot by the sum of the native and glutathionylated G-actin spots. During the preparation of glutathionylated G-actin, native G-actin also was recycled to ensure that apart from the glutathionylation, the native and glutathionylated G-actin batches were handled similarly.

Light scattering of F-actin. The polymerization of actin was monitored by measuring the change in light scattering over time (11). Various concentrations of G-actin were dissolved in (in mM) 2 Tris·HCl, pH 8.0, 0.2 CaCl2, and 0.2 ATP and allowed to equilibrate to 25°C in a Shimadzu RF-5301 spectrofluorophotometer. Polymerization of actin was initiated by the addition of an equal volume of polymerization buffer (in mM: 200 KCl and 4 MgCl2), and followed by light scattering at 360 nm and 1 Hz. Data from three batches of 17%, 36%, and 38% glutathionylated G-actin were pooled. To determine the effect of Tm on actin polymerization, varying concentrations of Tm were dissolved in the polymerization buffer before addition to actin.

F-actin cosedimentation. For cosedimentation, 2 µM filamentous actin (F-actin) polymerized from either native G-actin or glutathionylated G-actin was mixed with varying concentrations of Tm in (in mM) 10 Tris·HCl, pH 8.0, 100 KCl, and 2 MgCl2 (30-µl total volume). The mixture was incubated at 4°C for 2 h and then centrifuged at 100,000 g for 30 min at 4°C. The recovered pellets, along with 25 ng of G-actin and Tm controls, were resolved by performing 12% (29:1) SDS-PAGE using 18 x 16-cm gels. The gels were silver stained (47), and bands were quantitated using densitometry. Binding curves were developed using the Hill equation to determine Kapp and nH values with IGOR Pro software (WaveMetrics, Lake Oswego, OR). For cosedimentation, data from two separate batches of 36% and 38% glutathionylated G-actin were pooled.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Changes in contractility with ischemia-reperfusion injury. An in vivo rat model was used to determine the effect of ischemia-reperfusion injury on Fmax, fiber stiffness, Ktr, Vmax, and the force-Ca2+ relationship of permeabilized cardiac muscle fibers (Fig. 1). Initially, the Ca2+-activated Fmax of permeabilized trabeculae from control perfused, ischemic, or ischemia-reperfused hearts were compared in the presence of 5 mM ATP and 25 mM CP. The Ca2+-activated Fmax produced was significantly reduced from 199 ± 32 mN/mm2 (n = 8) in perfused fibers to 57 ± 8 mN/mm2 (n = 5) (P < 0.05) in ischemic fibers. The Fmax of reperfused fibers (127 ± 16 mN/mm2; n = 13) was significantly higher than that of ischemic fibers (P < 0.05), although there was not full recovery to the Fmax levels generated by perfused fibers. The EC50 increased significantly from 2.40 ± 0.11 µM [Ca2+] in perfused fibers to 3.31 ± 0.28 µM [Ca2+] in ischemic fibers (P < 0.05) but recovered with reperfusion to 1.86 ± 0.14 µM [Ca2+]. The cooperativity of force activation (i.e., Hill coefficient) for perfused fibers was 6.28 ± 1.21, which was not significantly different from that in ischemic fibers (5.44 ± 0.47) or ischemia-reperfused fibers (5.38 ± 1.01). Fiber stiffness also declined significantly from 2.16 ± 0.28 N/mm2 in perfused fibers to 1.44 ± 0.17 N/mm2 in ischemic fibers (P < 0.05) but recovered in reperfused fibers to 2.18 ± 0.26 N/mm2 (P < 0.05 vs. ischemic fibers). This decline in steady-state force and stiffness suggests that Ktr might also be impaired with ischemia. Fibers were maximally Ca2+ activated in the presence of 5 mM ATP and 25 mM CP, and then Ktr values were measured. Similarly to the Fmax data, fibers from ischemic hearts showed the largest decline in Ktr, demonstrating a 44% drop from 12.43 ± 0.28 s–1 in perfused fibers to 6.96 ± 0.38 s–1 in ischemic fibers. The observed decrease in Ktr with ischemia was largely recovered with reperfusion (11.00 ± 0.32 s–1; P < 0.05 vs. ischemic fibers). To complement the measures of permeabilized fiber contraction under external load, Vmax was determined to provide a contrasting measure in the absence of external load. In contrast to the Fmax and Ktr results, Vmax values were not statistically different from control, ischemic, or ischemia-reperfused heart fibers (Table 1).


Figure 1
View larger version (14K):
[in this window]
[in a new window]
  		Fig. 1. The force-Ca2+ relationship of perfused, ischemic, and ischemia-reperfused fibers. Trabeculae from perfused, ischemic, and ischemia-reperfused rat hearts were permeabilized and activated with varying Ca2+ concentrations ([Ca2+]) in the presence of 5 mM Mg2+-ATP and 25 mM creatine phosphate (CP). The representative force-Ca2+ relationships from perfused, ischemic, and ischemia-reperfused fibers are shown. For the representative perfused fiber ({circ}), the Ca502+ was 2.22 x 10–6 M and the Hill coefficient (nH) was 9.61. For the ischemic ({blacksquare}) and ischemia-reperfused fibers ({blacktriangleup}), the Ca502+ values were 3.24 x 10–6 M and 1.71 x 10–6 M, respectively, whereas nH values were 5.08 and 5.14, respectively.

 

View this table:
[in this window]
[in a new window]
  		Table 1. Contraction parameters from perfused, ischemic, and ischemia-reperfusion injury fibers

 
Effect of ischemia-reperfusion injury on thin-filament proteins. The contraction measurements in permeabilized fibers in the rat model suggest an effect of ischemia-reperfusion injury on the actomyosin filaments that resulted in impaired force generation against an external load. To explain these observations, previous studies demonstrated that ischemia-reperfusion injury of the heart may be accompanied by cleavage of thin-filament proteins. Specifically, TnI degradation was observed in models of ischemia-reperfusion injury and was postulated to be a mechanism contributing to the depressed contractility of the myocardium (41, 54). In addition, recent data have suggested that TnT also may be a target of proteolysis (12, 13, 41). To examine these possibilities, left ventricular homogenates from perfused, ischemic, and ischemia-reperfused hearts were immunoblotted for cardiac TnI and TnT. Western blot analysis showed that the TnI 88-106 antibody did not detect degraded TnI under the tested conditions (Fig. 2). Examination of TnT in the left ventricular homogenates revealed an abundant low Mr isoform corresponding to the predominant adult isoform as well as a much less abundant, higher Mr isoform (29). However, no proteolytic fragments of TnT were observed. These results suggest that appreciable degradation of the thin-filament proteins TnI and TnT did not occur during the ischemia or reperfusion conditions tested.


Figure 2
View larger version (30K):
[in this window]
[in a new window]
  		Fig. 2. Analysis of troponin I (TnI) and troponin T (TnT) in ischemia-reperfused hearts. Equal amounts of protein from the fiber homogenates of the ischemia-reperfusion injury model were resolved by performing SDS-PAGE. Subsequently, TnI and TnT expression from control, ischemic, or ischemia-reperfused hearts was examined using Western blot analysis. Under the conditions examined, both TnI and TnT remained intact, without evidence of proteolytic fragments.

 
In contrast to protein degradation, pathophysiological conditions that increase intracellular oxidative stress may result in covalent modification of proteins in situ. Previous studies have demonstrated that actin may be glutathionylated at COOH-terminal Cys374 as a result of oxidative stress (19, 20, 55, 56). Because glutathionylation has been suggested to be a modulator of protein activity (44, 55, 56), the possible glutathionylation of actin during ischemia was examined. Total profiles of perfused and ischemic heart homogenates were resolved by performing SDS-PAGE in the absence of an alkylator and immunoblotted using an anti-glutathione antibody (Fig. 3A). Both constitutively glutathionylated and selectively glutathionylated bands were observed under these conditions. Notably, a protein that migrated consistently with actin was observed to be glutathionylated in total ischemic extracts but was largely absent from total perfused extracts (Fig. 3A). This signal, although absent in the perfused sample, could also be abolished in the ischemic sample by treatment with DTT (Fig. 3B). In ischemic heart homogenates, an additional acidic actin isoelectric variant was observed on Western blot following two-dimensional SDS-PAGE, consistent with glutathionylation (Fig. 3C). This variant was abolished effectively after treatment with DTT, a sulfhydryl-reducing agent. Using densitometric quantitation, we found that the isoelectric point variant of actin accounted for 22 ± 6% (n = 4) of total actin in ischemic homogenates, reaching levels as high as 37% of total actin. To further ensure that this glutathionylated protein was actin, immunoprecipitation experiments were performed. Using homogenates from permeabilized ischemic left ventricles, the anti-actin antibody was used to immunoprecipitate actin under actin-depolymerizing conditions. The immunoprecipitated protein was then resolved by performing SDS-PAGE and subjected to Western blot analysis with either anti-actin or anti-glutathione antibody (Fig. 3D). The results demonstrate that the immunoprecipitated actin was also glutathionylated, confirming the nature of the posttranslational modification of actin. Furthermore, the use of extracts from permeabilized trabeculae suggests that the immunoprecipitated actin was derived largely from F-actin and therefore represents glutathionylated actin monomers that were integrated into the thin filaments. Nonetheless, additional experiments are required to absolutely exclude the possible contribution of nonfilamentous, free G-actin to the presented results.


Figure 3
View larger version (32K):
[in this window]
[in a new window]
  		Fig. 3. Glutathionylation of actin in vivo. A: homogenates from perfused and ischemic hearts were examined using Western blot analysis with an anti-glutathione antibody. B: immunoreactivity of a band that migrated consistently with actin was observed in ischemic homogenates but was absent from the perfused sample and was eliminated by DTT treatment. C: two-dimensional SDS-PAGE followed by Western blot analysis using an actin antibody demonstrated an additional actin isoelectric point variant that was abolished by DTT treatment of the ischemic homogenate. D: actin was immunoprecipitated from homogenates of ischemic fibers. Immunoprecipitated actin was shown to be glutathionylated as determined by Western blot analysis using anti-glutathione antibody.

 
Effect of glutathionylation on actin polymerization. To examine the effect of glutathionylation on actin's function, purified G-actin was glutathionylated in vitro at Cys374 according to established protocols (16, 18). The in vitro glutathionylation of G-actin was verified using Western blot analysis with the anti-glutathione antibody (Fig. 4). Furthermore, only one additional isoelectric variant of G-actin was evident on the basis of two-dimensional SDS-PAGE, consistent with glutathionylation at a single site (Fig. 4) (16). Quantitation of the actin isoelectric variants resolved by performing two-dimensional SDS-PAGE demonstrated that 30 ± 8% of the actin (n = 3) was glutathionylated, which is within the maximum level observed in vivo. Using F-actin light scattering, we determined the effect of G-actin glutathionylation on actin polymerization at three concentrations of total (glutathionylated + native) G-actin monomer. Pooled data from preparations of 17%, 36%, and 38% glutathionylated actin were compared with native G-actin preparations. Although the times for half-maximal actin polymerization were dependent on the starting monomer concentration (30) for both native and glutathionylated G-actin, glutathionylated G-actin polymerized slower than native G-actin at all concentrations tested (Fig. 5A). As a reference point, the time required for half-maximal polymerization of 10 µM native G-actin was 91 ± 3 s (n = 5), compared with 231 ± 21 s (n = 3) (P < 0.05) for glutathionylated G-actin. The maximum extent of polymerization was also reduced for glutathionylated G-actin compared with native G-actin (data not shown), consistent with prior work (55). In an additional set of polymerization experiments, a 10 µM solution of 38% glutathionylated G-actin was mixed with varying proportions of 10 µM native G-actin to reduce the relative amount of glutathionylated G-actin monomer while keeping the total monomer concentration constant. As the proportion of glutathionylated G-actin was reduced, the times for half-maximal polymerization were reduced in concert (Fig. 5B). This finding suggests that the effect of glutathionylated G-actin on actin polymerization kinetics was proportional across the range of glutathionylated monomer tested.


Figure 4
View larger version (30K):
[in this window]
[in a new window]
  		Fig. 4. In vitro glutathionylation of globular actin (G-actin). Purified G-actin glutathionylated in vitro and examined using Western blot analysis with anti-glutathione antibody is shown at left. After glutathionylation, the anti-glutathione antibody identified the in vitro modified G-actin, and this signal was abolished by DTT treatment. To determine the extent of glutathionylation, an aliquot of glutathionylated G-actin was resolved by performing two-dimensional PAGE and silver stained. An aliquot of G-actin that was 38% glutathionylated is shown at right.

 

Figure 5
View larger version (35K):
[in this window]
[in a new window]
  		Fig. 5. Effect of glutathionylation on actin polymerization. Polymerization of native or glutathionylated actin was studied using light scattering. A: using 5, 7.5, or 10 µM total monomer, native or glutathionylated G-actin was polymerized by adding KCl to 100 mM and MgCl2 to 2 mM concentration. At all concentrations tested, polymerization of glutathionylated G-actin lagged that of native G-actin. B: to determine the effect of the extent of glutathionylation on actin polymerization, a 10 µM 38% glutathionylated G-actin sample was mixed with varying proportions of 10 µM native G-actin.

 
Effect of actin glutathionylation on the interaction with Tm. To further examine the impact of actin glutathionylation, its effect on the allosteric actin-Tm interaction was investigated (64). Actin polymerization experiments were conducted using either native or 38% glutathionylated G-actin in the presence of varying Tm concentrations. When mixed with 10 µM native G-actin, increasing concentrations of Tm dimer reduced the time required for half-maximal polymerization (Fig. 6A). However, at all Tm concentrations tested, the time course of polymerization for glutathionylated G-actin lagged that of native G-actin (Fig. 6B). The affinity of Tm for glutathionylated actin was determined by performing F-actin cosedimentation experiments using 2 µM native or glutathionylated F-actin and varying concentrations of Tm dimers (Fig. 7). Data from two batches of 36% and 38% glutathionylated F-actin were pooled. As determined using Hill fits of the data, Kapp for Tm binding to native F-actin was 3.4 ± 1.2 x 106 M–1 (n = 4) vs. 2.5 ± 0.9 x 106 M–1 (n = 4) for glutathionylated F-actin. The difference in these binding constants was not statistically significant. The Hill coefficient defining the cooperativity of the interaction between Tm and native F-actin was 2.84 ± 0.55 (n = 4), in contrast to 1.53 ± 0.28 (n = 4) for the interaction between Tm and glutathionylated F-actin. This difference in the cooperativity of Tm binding to F-actin was statistically significant (P < 0.05).


Figure 6
View larger version (26K):
[in this window]
[in a new window]
  		Fig. 6. Effect of tropomyosin (Tm) on actin polymerization. Effect of Tm on polymerization of native and glutathionylated G-actin was examined using light scattering. Using 10 µM actin monomer, either native G-actin (A) or 38% glutathionylated G-actin (B) was mixed with varying concentrations of Tm dimer. Although Tm accelerated polymerization of both native and glutathionylated G-actin in a concentration-dependent manner, times required for half-maximal polymerization of glutathionylated actin remained slower than those required for native actin.

 

Figure 7
View larger version (17K):
[in this window]
[in a new window]
  		Fig. 7. Actin-Tm cosedimentation. Cosedimentation experiments were conducted to determine affinity and cooperativity of binding between Tm and either native or glutathionylated 2 µM filamentous actin (F-actin). Affinity of Tm for glutathionylated F-actin (Kapp = 2.5 ± 0.9 x 106 M–1) did not differ significantly from its affinity for native F-actin (Kapp = 3.4 ± 1.2 x 106 M–1). However, the cooperativity of Tm binding to glutathionylated F-actin was significantly decreased (2.84 ± 0.55 vs. 1.53 ± 0.28; P < 0.05).

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
In the present study, we used an in vivo rat model of ischemia-reperfusion injury to examine force generation by permeabilized trabeculae after Ca2+ activation. The novel findings derived using this model stem from the observation that force generation by ischemic myocardium was depressed independent of ATP availability and that this deficit was largely recovered during reperfusion. These findings suggest that ischemia triggered intrinsic changes in the contractile filaments that altered their ability to generate force despite ATP availability. To better understand this decline in force generation by the permeabilized fibers, various contractile parameters, such as Fmax, Ktr, Vmax, and fiber stiffness, were measured and complemented with data on the force-Ca2+ relationships of the fibers. We have demonstrated that measures of fiber contraction under external load were affected adversely by ischemia but were largely recovered by reperfusion. Specifically, the decline in Fmax and fiber stiffness associated with ischemia suggest that these alterations to the contractile apparatus adversely affect the activation of thin-filament regulatory units, resulting in a decline in attached cross bridges and, consequently, force (Table 1). However, we also note that despite the full recovery of fiber stiffness upon reperfusion from the ischemic state, the recovery of Fmax was not complete. This divergence suggests that the intrinsic changes to the contractile filaments with ischemia may work to shift attached cross bridges to low- or non-force-producing states, rationalizing the remaining Fmax deficit during reperfusion despite the full recovery of fiber stiffness. Future experiments focusing on ADP or Pi-dependent transitions of the cross-bridge cycle may better describe the cause of the divergence in force and fiber stiffness during reperfusion.

The reversible decline in force generation of the permeabilized fibers also suggests that proteins of the contractile filaments may be altered during ischemia-reperfusion injury. Previous research demonstrated that proteolytic degradation of the thin-filament proteins TnI and TnT may contribute to myocardial stunning (12, 41, 54). Proteolysis would be consistent with a hypothesized change to the actomyosin filaments that could alter contractility independent of ATP availability. However, the decline in force generation with ischemia was largely recovered by reperfusion, indicating that proteolysis would need to be recovered rapidly by protein synthesis and reintegration within 60 min of reperfusion. Although this consideration indirectly suggests that proteolysis was not a major contributor to the decline in force generation observed in this model, it was confirmed using Western blot analysis for TnI and TnT, two subunits of the troponin complex that were previously observed to be truncated in alternate models (Fig. 2).

Rather than proteolysis of thin-filament proteins, the data present suggest that alternate modifications to proteins of the actomyosin filaments occurred with ischemia. Prior research established that actin may be glutathionylated in response to cellular oxidative stress, resulting in the modification of the physiologically labile COOH-terminal Cys residue (55). In the present study, examination of ischemic heart homogenates demonstrated that actin was glutathionylated in our in vivo model (Fig. 3), suggesting that actin may be a novel contributor to the observed change in force generation with ischemia. Because we analyzed proteins from permeabilized fibers in the present study, these findings suggest that the glutathionylated actin was myofibrillar rather than monomeric G-actin in a soluble pool. The impact of actin glutathionylation was tested in vitro using purified G-actin that had been glutathionylated at the COOH-terminal Cys (Fig. 4). The time course of polymerization for glutathionylated G-actin lagged that of native G-actin at all concentrations tested (Fig. 5A), in agreement with previous observations (16, 55). This decrease in polymerization was proportional to the percentage of glutathionylated G-actin monomer present, suggesting that the impact of this covalent modification on actin's function depended on the fraction of actin in the thin filament that was glutathionylated in situ during ischemia-reperfusion injury (Fig. 5B). In prior work, it was demonstrated that in vitro modification of this COOH-terminal end of actin, through either glutathionylation or amino acid removal, destabilized actin filaments as well as supporting actin filament reorganization (17, 40, 51, 56). It was therefore postulated that the deficit in polymerization of glutathionylated actin could be rescued by stabilizing the actin-actin contacts with Tm. Although Tm decreased the time required for half-maximal polymerization in all cases, the time course of polymerization for glutathionylated G-actin remained slower than that for native G-actin (Fig. 6). Therefore, the data reported in the present study suggest that glutathionylation of actin within the observed physiological range impaired actin intermonomer contacts.

These findings were further investigated by determining the affinity of Tm for native and glutathionylated F-actin. Tm's inability to rescue the polymerization activity of glutathionylated actin may have been interpreted as a decrease in Tm affinity for glutathionylated actin. However, cosedimentation experiments did not reveal a significant difference in Tm affinity for native vs. glutathionylated F-actin. Rather, a statistically significant decline in the cooperativity of Tm binding to glutathionylated F-actin was observed (Fig. 7). Although there are no data supporting direct contact of Tm with Cys374 of actin (37), the cosedimentation results suggest that the allosteric interaction between Tm and actin was affected by actin glutathionylation. This finding is consistent with the results of prior work suggesting that cooperative binding of Tm to F-actin involved conformational changes propagated along the actin filament subsequent to Tm binding (8, 25, 38, 59). These allosteric changes in actin after Tm binding are supported by cross-linking experiments demonstrating that contact between myosin S1 and actin residues 48–67 could be abrogated by the presence of Tm (3), despite the absence of direct contact between Tm and actin at these residues (36). In addition, cleavage between residues 42 and 43 of the DNase I binding loop of actin attenuated the inhibitory effect of Tm on actin-activated myosin S1 ATPase activity (38), suggesting that the DNase I binding loop is sensitive to conformational changes subsequent to Tm binding. These data complement data regarding the intermonomer interactions of actin indicating that the DNase I binding loop and the COOH-terminal Cys374 of the adjacent actin are sufficiently close in proximity to be cross linked efficiently by an ~12-Å linker (26). Specifically, Gln41 of actin was cross-linked to Cys374 of the laterally adjacent actin, indicative of intermonomer coupling between actins. These results suggest that in situ glutathionylation of actin in the thin filament during ischemia-reperfusion injury may alter the contractile performance of the myocardium. Glutathionylation may modify actin intermonomer interactions that take place subsequent to Tm dimers shifting with thin-filament activation. Alternatively, the noted shift of Tm during muscle activation may be impaired by the change in actin intermonomer contacts due to glutathionylation. This cross talk between actin and Tm is consistent with observations that cooperative Tm binding to actin is dependent on a degree of propagation through the actin filament (25) and builds on the observation that Tm binding to actin produces a conformational change within the actin filament (8). Additional experiments are necessary to develop a better understanding of the impact of altered actin-Tm interactions on force generation. Along these lines, previous work examining a Tm mutation associated with human cardiomyopathies demonstrated a weakened interaction between the mutant Tm and actin in vitro (23). Nonetheless, the impact of this mutation in fibers was observed as a change in the Ca2+ sensitivity of force generation (4). Because the Tm-actin interaction itself is not Ca2+ sensitive, it is not entirely clear how changes in the interaction of these two proteins predicts the observed effect of sensitizing fibers to Ca2+. In light of these data, it is not clear whether the change in the cooperativity of association observed in the present study (Fig. 7) must translate specifically to a decrease in the cooperativity of force activation, although a small decline in nH was observed (Table 1). However, glutathionylated actin's possible contribution to Ca2+ desensitization during ischemia cannot be ruled out. Future studies detailing the effect of actin glutathionylation will require a methodical characterization of its interaction with other individual thin-filament proteins, as well as its effect on the regulated in vitro actomyosin ATPase. These studies will lead to more comprehensive models to describe the allosteric interactions that regulate force generation by the contractile filaments.

Additional experiments are also warranted to examine the multifocal effect of ischemia and ischemia-reperfusion injury on cross-bridge activation in muscle fibers. A large body of evidence suggests that beyond ATP availability, posttranslational modifications such as protein oxidation or phosphorylation (52, 53) of contractile filament proteins also underlie the observed net change in force generation by the myocardium, especially for acute conditions in which ventricular remodeling cannot be a factor. Therefore, future experiments will require comprehensive in vitro systems to examine the impact of unique posttranslational modifications effectively, not only by themselves but also in combination. Such an integrated approach will better define the deleterious and protective modifications whose net impact defines the function of the contractile apparatus during and after ischemia-reperfusion injury.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by Beginning Grant-in-Aid 0365170B from the American Heart Association–Ohio Valley Affiliate.


   ACKNOWLEDGMENTS
 
We thank Dr. Frank Brozovich, Dr. Luke Szweda, Dr. Hesham Sadek, Kathleen Lundberg, Dan Stofan, and Bridgette Christopher for invaluable contributions.


   FOOTNOTES
 

Address for reprint requests and other correspondence: O. Ogut, Cardiovascular Contractility and Signaling Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Guggenheim 9-06, 200 First Ave. SW, Rochester, MN 55905 (e-mail: ogut.ozgur{at}mayo.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
1. Berlett BS and Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 272: 20313–20316, 1997.[Free Full Text]

2. Bolli R, Patel BS, Jeroudi MO, Lai EK, and McCay PB. Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap {alpha}-phenyl N-tert-butyl nitrone. J Clin Invest 82: 476–485, 1988.[ISI][Medline]

3. Bonafé N, Mathieu M, Kassab R, and Chaussepied P. Tropomyosin inhibits the glutaraldehyde-induced cross-link between the central 48-kDa fragment of myosin head and segment 48–67 in actin subdomain 2. Biochemistry 33: 2594–2603, 1994.[CrossRef][Medline]

4. Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P, Watkins H, and Reggiani C. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res 82: 106–115, 1998.[Abstract/Free Full Text]

5. Bottomley PA, Herfkens RJ, Smith LS, and Bashore TM. Altered phosphate metabolism in myocardial infarction: P-31 MR spectroscopy. Radiology 165: 703–707, 1987.[Abstract/Free Full Text]

6. Bottomley PA and Weiss RG. Noninvasive localized MR quantification of creatine kinase metabolites in normal and infarcted canine myocardium. Radiology 219: 411–418, 2001.[Abstract/Free Full Text]

7. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B, and Szweda LI. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276: 30057–30063, 2001.[Abstract/Free Full Text]

8. Butters CA, Willadsen KA, and Tobacman LS. Cooperative interactions between adjacent troponin-tropomyosin complexes may be transmitted through the actin filament. J Biol Chem 268: 15565–15570, 1993.[Abstract/Free Full Text]

9. Cave AC, Ingwall JS, Friedrich J, Liao R, Saupe KW, Apstein CS, and Eberli FR. ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation 101: 2090–2096, 2000.[Abstract/Free Full Text]

10. Chase P and Kushmerick MJ. Effects of pH on contraction of rabbit fast and slow skeletal muscle fibers. Biophys J 53: 935–946, 1988.[Abstract/Free Full Text]

11. Chen X and Rubenstein PA. A mutation in an ATP-binding loop of Saccharomyces cerevisiae actin (S14A) causes a temperature-sensitive phenotype in vivo and in vitro. J Biol Chem 270: 11406–11414, 1995.[Abstract/Free Full Text]

12. Colantonio DA, Van Eyk JE, and Przyklenk K. Stunned peri-infarct canine myocardium is characterized by degradation of troponin T, not troponin I. Cardiovasc Res 63: 217–225, 2004.[Abstract/Free Full Text]

13. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, and Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 99: 6252–6256, 2002.[Abstract/Free Full Text]

14. Cooke R and Bialek W. Contraction of glycerinated muscle fibers as a function of the ATP concentration. Biophys J 28: 241–258, 1979.[Abstract/Free Full Text]

15. Corti R, Fuster V, and Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 41, Suppl 1: 7S–14S, 2003.[Abstract/Free Full Text]

16. Dalle-Donne I, Giustarini D, Rossi R, Colombo R, and Milzani A. Reversible S-glutathionylation of Cys 374 regulates actin filament formation by inducing structural changes in the actin molecule. Free Radic Biol Med 34: 23–32, 2003.[CrossRef][ISI][Medline]

17. Drewes G and Faulstich H. Cooperative effects on filament stability in actin modified at the C-terminus by substitution or truncation. Eur J Biochem 212: 247–253, 1993.[ISI][Medline]

18. Drewes G and Faulstich H. The enhanced ATPase activity of glutathione-substituted actin provides a quantitative approach to filament stabilization. J Biol Chem 265: 3017–3021, 1990.[Abstract/Free Full Text]

19. Eaton P, Byers HL, Leeds N, Ward MA, and Shattock MJ. Detection, quantitation, purification, and identification of cardiac proteins S-thiolated during ischemia and reperfusion. J Biol Chem 277: 9806–9811, 2002.[Abstract/Free Full Text]

20. Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, Salmona M, Bonetto V, Mengozzi M, Duffieux F, Miclet E, Bachi A, Vandekerckhove J, Gianazza E, and Ghezzi P. Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc Natl Acad Sci USA 99: 3505–3510, 2002.[Abstract/Free Full Text]

21. Friguet B, Szweda LI, and Stadtman ER. Susceptibility of glucose-6-phosphate dehydrogenase modified by 4-hydroxy-2-nonenal and metal-catalyzed oxidation to proteolysis by the multicatalytic protease. Arch Biochem Biophys 311: 168–173, 1994.[CrossRef][ISI][Medline]

22. Gao WD, Atar D, Liu YG, Pérez NG, Murphy AM, and Marbán E. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res 80: 393–399, 1997.[ISI][Medline]

23. Golitsina N, An Y, Greenfield NJ, Thierfelder L, Iizuka K, Seidman JG, Seidman CE, Lehrer SS, and Hitchcock-DeGregori SE. Effects of two familial hypertrophic cardiomyopathy-causing mutations on {alpha}-tropomyosin structure and function. Biochemistry 36: 4637–4642, 1997.[CrossRef][Medline]

24. Hardy CJ, Weiss RG, Bottomley PA, and Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 122: 795–801, 1991.[CrossRef][ISI][Medline]

25. Heald RW and Hitchcock-DeGregori SE. The structure of the amino terminus of tropomyosin is critical for binding to actin in the absence and presence of troponin. J Biol Chem 263: 5254–5259, 1988.[Abstract/Free Full Text]

26. Hegyi G, Mak M, Kim E, Elzinga M, Muhlrad A, and Reisler E. Intrastrand cross-linked actin between Gln-41 and Cys-374. I. Mapping of sites cross-linked in F-actin by N-(4-azido-2-nitrophenyl) putrescine. Biochemistry 37: 17784–17792, 1998.[CrossRef][Medline]

27. Hill AV. The heat of shortening and the dynamic constants of muscle. Proc R Soc Lond B Biol Sci 126: 136–195, 1938.

28. Jennings RB, Murry CE, Steenbergen C Jr, and Reimer KA. Development of cell injury in sustained acute ischemia. Circulation 82: II2–II12, 1990.[Medline]

29. Jin JP and Lin JJ. Rapid purification of mammalian cardiac troponin T and its isoform switching in rat hearts during development. J Biol Chem 263: 7309–7315, 1988.[Abstract/Free Full Text]

30. Kang F, Purich DL, and Southwick FS. Profilin promotes barbed-end actin filament assembly without lowering the critical concentration. J Biol Chem 274: 36963–36972, 1999.[Abstract/Free Full Text]

31. Klatt P, Pineda Molina E, García De Lacoba M, Padilla CA, Martínez-Galesteo E, Bárcena JA, and Lamas S. Redox regulation of c-Jun DNA binding by reversible S-glutathiolation. FASEB J 13: 1481–1490, 1999.[Abstract/Free Full Text]

32. Klatt P, Pineda Molina E, and Lamas S. Nitric oxide inhibits c-Jun DNA binding by specifically targeted S-glutathionylation. J Biol Chem 274: 15857–15864, 1999.[Abstract/Free Full Text]

33. Kloner RA, Ganote CE, Whalen DA Jr, and Jennings RB. Effect of a transient period of ischemia on myocardial cells. II. Fine structure during the first few minutes of reflow. Am J Pathol 74: 399–422, 1974.[ISI][Medline]

34. Kögler H, Soergel DG, Murphy AM, and Marbán E. Maintained contractile reserve in a transgenic mouse model of myocardial stunning. Am J Physiol Heart Circ Physiol 280: H2623–H2630, 2001.[Abstract/Free Full Text]

35. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, and Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277: 20336–20342, 2002.[Abstract/Free Full Text]

36. Lorenz M, Poole KJV, Popp D, Rosenbaum G, and Holmes KC. An atomic model of the unregulated thin filament obtained by X-ray fiber diffraction on oriented actin-tropomyosin gels. J Mol Biol 246: 108–119, 1995.[CrossRef][ISI][Medline]

37. Milligan RA, Whittaker M, and Safer D. Molecular structure of F-actin and location of surface binding sites. Nature 348: 217–221, 1990.[CrossRef][Medline]

38. Moraczewska J, Gruszczynska-Biegala J, Redowicz MJ, Khaitlina SY, and Strzelecka-Golaszewska H. The DNase-I binding loop of actin may play a role in the regulation of actin-myosin interaction by tropomyosin/troponin. J Biol Chem 279: 31197–31204, 2004.[Abstract/Free Full Text]

39. Moskovitz J, Bar-Noy S, Williams WM, Requena J, Berlett BS, and Stadtman ER. Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc Natl Acad Sci USA 98: 12920–12925, 2001.[Abstract/Free Full Text]

40. Mossakowska M, Moraczewska J, Khaitlina S, and Strzelecka-Golaszewska H. Proteolytic removal of three C-terminal residues of actin alters the monomer-monomer interactions. Biochem J 289: 897–902, 1993.

41. Murphy AM, Kögler H, Georgakopoulos D, McDonough JL, Kass DA, Van Eyk JE, and Marbán E. Transgenic mouse model of stunned myocardium. Science 287: 488–491, 2000.[Abstract/Free Full Text]

42. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, and Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96: 2190–2196, 1997.[Abstract/Free Full Text]

43. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GAJ, Lackner K, and Ertl G. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease: altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86: 1810–1818, 1992.[Abstract/Free Full Text]

44. Nulton-Persson AC, Starke DW, Mieyal JJ, and Szweda LI. Reversible inactivation of {alpha}-ketoglutarate dehydrogenase in response to alterations in the mitochondrial glutathione status. Biochemistry 42: 4235–4242, 2003.[CrossRef][Medline]

45. Ogut O and Brozovich FV. Creatine phosphate consumption and the actomyosin crossbridge cycle in cardiac muscles. Circ Res 93: 54–60, 2003.[Abstract/Free Full Text]

46. Ogut O, Granzier H, and Jin JP. Acidic and basic troponin T isoforms in mature fast-twitch skeletal muscle and effect on contractility. Am J Physiol Cell Physiol 276: C1162–C1170, 1999.[Abstract/Free Full Text]

47. Ogut O, Hossain MM, and Jin JP. Interactions between nebulin-like motifs and thin filament regulatory proteins. J Biol Chem 278: 3089–3097, 2003.[Abstract/Free Full Text]

48. Pardee JD and Spudich JA. Purification of muscle actin. Methods Enzymol 85: 164–181, 1982.

49. Shringarpure R and Davies KJA. Protein turnover by the proteasome in aging and disease. Free Radic Biol Med 32: 1084–1089, 2002.[CrossRef][ISI][Medline]

50. Smillie LB. Preparation and identification of {alpha}- and beta-tropomyosins. Methods Enzymol 85: 234–241, 1982.

51. Stournaras C, Drewes G, Blackholm H, Merkler I, and Faulstich H. Glutathionyl(cysteine-374) actin forms filaments of low mechanical stability. Biochim Biophys Acta 1037: 86–91, 1990.[CrossRef][Medline]

52. Van der Velden J, Papp Z, Boontje NM, Zaremba R, de Jong JW, Janssen PML, Hasenfuss G, and Stienen GJM. The effect of myosin light chain 2 dephosphorylation on Ca2+-sensitivity of force is enhanced in failing human hearts. Cardiovasc Res 57: 505–514, 2003.[Abstract/Free Full Text]

53. Van der Velden J, Papp Z, Boontje NM, Zaremba R, de Jong JW, Janssen PM, Hasenfuss G, and Stienen GJ. Myosin light chain composition in non-failing donor and end-stage failing human ventricular myocardium. Adv Exp Med Biol 538: 3–15, 2003.[ISI][Medline]

54. Van Eyk JE, Powers F, Law W, Larue C, Hodges RS, and Solaro RJ. Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ Res 82: 261–271, 1998.[Abstract/Free Full Text]

55. Wang J, Boja ES, Tan W, Tekle E, Fales HM, English S, Mieyal JJ, and Chock PB. Reversible glutathionylation regulates actin polymerization in A431 cells. J Biol Chem 276: 47763–47766, 2001.[Abstract/Free Full Text]

56. Wang J, Tekle E, Oubrahim H, Mieyal JJ, Stadtman ER, and Chock PB. Stable and controllable RNA interference: investigating the physiological function of glutathionylated actin. Proc Natl Acad Sci USA 100: 5103–5106, 2003.[Abstract/Free Full Text]

57. Webb A, Bond R, McLean P, Uppal R, Benjamin N, and Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci USA 101: 13683–13688, 2004.[Abstract/Free Full Text]

58. Westfall MV and Solaro RJ. Alterations in myofibrillar function and protein profiles after complete global ischemia in rat hearts. Circ Res 70: 302–313, 1992.[Abstract/Free Full Text]

59. Willadsen KA, Butters CA, Hill LE, and Tobacman LS. Effects of the amino-terminal regions of tropomyosin and troponin T on thin filament assembly. J Biol Chem 267: 23746–23752, 1992.[Abstract/Free Full Text]

60. Woo HA, Chae HZ, Hwang SC, Yang KS, Kang SW, Kim K, and Rhee SG. Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. Science 300: 653–656, 2003.[Abstract/Free Full Text]

61. Woo HA, Kang SW, Kim HK, Yang KS, Chae HZ, and Rhee SG. Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfinic acid: immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing sequence. J Biol Chem 278: 47361–47364, 2003.[Abstract/Free Full Text]

62. Yabe T, Mitsunami K, Inubushi T, and Kinoshita M. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation 92: 15–23, 1995.[Abstract/Free Full Text]

63. Zingarelli B, Hake PW, Yang Z, O'Connor M, Denenberg A, and Wong HR. Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-{kappa}B and AP-1 activation and enhances myocardial damage. FASEB J 16: 327–342, 2002.[Abstract/Free Full Text]

64. Zot AS and Potter JD. Structural aspects of troponin-tropomyosin regulation of skeletal muscle contraction. Annu Rev Biophys Biophys Chem 16: 535–559, 1987.[CrossRef][ISI][Medline]




This article has been cited by other articles:


Home page
 Mol. Interv.Home page
D. M. Townsend
S-Glutathionylation: Indicator of Cell Stress and Regulator of the Unfolded Protein Response
Mol. Interv., December 1, 2007; 7(6): 313 - 324.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
A. M. Given, O. Ogut, and F. V. Brozovich
MYPT1 mutants demonstrate the importance of aa 888-928 for the interaction with PKGI{alpha}
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C432 - C439.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
B. J. Biesiadecki and R. J. Solaro
When Hearts Fail So Does Skeletal Muscle: Breaking a Vicious Cycle
Circ. Res., June 23, 2006; 98(12): 1456 - 1458.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/3/C719    most recent
00419.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services